



Erratum: Molecular, Immunological, and Clinical Features Associated With Lymphoid Neogenesis in Muscle Invasive Bladder Cancer

Frontiers Production Office

Frontiers Media SA, Lausanne, Switzerland

OPEN ACCESS

Approved by:

Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*Correspondence:

production.office@frontiersin.org

Specialty section:

This article was submitted to
Cancer Immunity
and Immunotherapy,
a section of the journal
Frontiers in Immunology

Received: 22 June 2022

Accepted: 22 June 2022

Published: 04 July 2022

Citation:

Frontiers Production Office (2022)
Erratum: Molecular, Immunological,
and Clinical Features Associated
With Lymphoid Neogenesis in
Muscle Invasive Bladder Cancer.
Front. Immunol. 13:975797.
doi: 10.3389/fimmu.2022.975797

Keywords: tertiary lymphoid structures, lymphoid neogenesis, tumor mutational burden, cancer immunology, immune checkpoint inhibition, survival, prognosis, tumor microenvironment

An Erratum on:

Molecular, Immunological, and Clinical Features Associated With Lymphoid Neogenesis in Muscle Invasive Bladder Cancer.

Pagliariulo F, Cheng PF, Brugger L, van Dijk N, van den Heijden M, Levesque MP, Silina K and van den Broek M (2022) Front. Immunol. 12:793992. doi: 10.3389/fimmu.2021.793992

Due to a production error, **Supplementary Figures 2,3,5,6,7,8 and 9** were not published. The publisher apologizes for this mistake.

The original version of this article has been updated.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fimmu.2022.975797/full#supplementary-material>

Copyright © 2022 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.